Cargando…

CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers

Variation in the penetrance estimates for BRCA1 and BRCA2 mutations carriers suggests that other genetic polymorphisms may modify the cancer risk in carriers. A previous study has suggested that BRCA1 carriers with longer lengths of the CAG repeat in the androgen receptor (AR) gene are at increased...

Descripción completa

Detalles Bibliográficos
Autores principales: Kadouri, L, Easton, D F, Edwards, S, Hubert, A, Kote-Jarai, Z, Glaser, B, Durocher, F, Abeliovich, D, Peretz, T, Eeles, R A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363908/
https://www.ncbi.nlm.nih.gov/pubmed/11437399
http://dx.doi.org/10.1054/bjoc.2001.1777
_version_ 1782153821501259776
author Kadouri, L
Easton, D F
Edwards, S
Hubert, A
Kote-Jarai, Z
Glaser, B
Durocher, F
Abeliovich, D
Peretz, T
Eeles, R A
author_facet Kadouri, L
Easton, D F
Edwards, S
Hubert, A
Kote-Jarai, Z
Glaser, B
Durocher, F
Abeliovich, D
Peretz, T
Eeles, R A
author_sort Kadouri, L
collection PubMed
description Variation in the penetrance estimates for BRCA1 and BRCA2 mutations carriers suggests that other genetic polymorphisms may modify the cancer risk in carriers. A previous study has suggested that BRCA1 carriers with longer lengths of the CAG repeat in the androgen receptor (AR) gene are at increased risk of breast cancer (BC). We genotyped 188 BRCA1/2 carriers (122 affected and 66 unaffected with breast cancer), 158 of them of Ashkenazi origin, 166 BC cases without BRCA1/2 mutations and 156 Ashkenazi control individuals aged over 56 for the AR CAG and GGC repeats. In carriers, risk analyses were conducted using a variant of the log-rank test, assuming two sets of risk estimates in carriers: penetrance estimates based on the Breast Cancer Linkage Consortium (BCLC) studies of multiple case families, and lower estimates as suggested by population-based studies. We found no association of the CAG and GGC repeats with BC risk in either BRCA1/2 carriers or in the general population. Assuming BRCA1/2 penetrance estimates appropriate to the Ashkenazi population, the estimated RR per repeat adjusted for ethnic group (Ashkenazi and non-Ashkenazi) was 1.05 (95%CI 0.97–1.17) for BC and 1.00 (95%CI 0.83–1.20) for ovarian cancer (OC) for CAG repeats and 0.96 (95%CI 0.80–1.15) and 0.90 (95%CI 0.60–1.22) respectively for GGC repeats. The corresponding RR estimates for the unselected case–control series were 1.00 (95%CI 0.91–1.10) for the CAG and 1.05 (95%CI 0.90–1.22) for the GGC repeats. The estimated relative risk of BC in carriers associated with ≥28 CAG repeats was 1.08 (95%CI 0.45–2.61). Furthermore, no significant association was found if attention was restricted to the Ashkenazi carriers, or only to BRCA1 or BRCA2 carriers. We conclude that, in contrast to previous observations, if there is any effect of the AR repeat length on BRCA1 penetrance, it is likely to be weak. © 2001 Cancer Research Campaign http://www.bjcancer.com
format Text
id pubmed-2363908
institution National Center for Biotechnology Information
language English
publishDate 2001
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23639082009-09-10 CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers Kadouri, L Easton, D F Edwards, S Hubert, A Kote-Jarai, Z Glaser, B Durocher, F Abeliovich, D Peretz, T Eeles, R A Br J Cancer Regular Article Variation in the penetrance estimates for BRCA1 and BRCA2 mutations carriers suggests that other genetic polymorphisms may modify the cancer risk in carriers. A previous study has suggested that BRCA1 carriers with longer lengths of the CAG repeat in the androgen receptor (AR) gene are at increased risk of breast cancer (BC). We genotyped 188 BRCA1/2 carriers (122 affected and 66 unaffected with breast cancer), 158 of them of Ashkenazi origin, 166 BC cases without BRCA1/2 mutations and 156 Ashkenazi control individuals aged over 56 for the AR CAG and GGC repeats. In carriers, risk analyses were conducted using a variant of the log-rank test, assuming two sets of risk estimates in carriers: penetrance estimates based on the Breast Cancer Linkage Consortium (BCLC) studies of multiple case families, and lower estimates as suggested by population-based studies. We found no association of the CAG and GGC repeats with BC risk in either BRCA1/2 carriers or in the general population. Assuming BRCA1/2 penetrance estimates appropriate to the Ashkenazi population, the estimated RR per repeat adjusted for ethnic group (Ashkenazi and non-Ashkenazi) was 1.05 (95%CI 0.97–1.17) for BC and 1.00 (95%CI 0.83–1.20) for ovarian cancer (OC) for CAG repeats and 0.96 (95%CI 0.80–1.15) and 0.90 (95%CI 0.60–1.22) respectively for GGC repeats. The corresponding RR estimates for the unselected case–control series were 1.00 (95%CI 0.91–1.10) for the CAG and 1.05 (95%CI 0.90–1.22) for the GGC repeats. The estimated relative risk of BC in carriers associated with ≥28 CAG repeats was 1.08 (95%CI 0.45–2.61). Furthermore, no significant association was found if attention was restricted to the Ashkenazi carriers, or only to BRCA1 or BRCA2 carriers. We conclude that, in contrast to previous observations, if there is any effect of the AR repeat length on BRCA1 penetrance, it is likely to be weak. © 2001 Cancer Research Campaign http://www.bjcancer.com Nature Publishing Group 2001-07 /pmc/articles/PMC2363908/ /pubmed/11437399 http://dx.doi.org/10.1054/bjoc.2001.1777 Text en Copyright © 2001 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Kadouri, L
Easton, D F
Edwards, S
Hubert, A
Kote-Jarai, Z
Glaser, B
Durocher, F
Abeliovich, D
Peretz, T
Eeles, R A
CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers
title CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers
title_full CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers
title_fullStr CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers
title_full_unstemmed CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers
title_short CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers
title_sort cag and ggc repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in brca1/2 carriers and non-carriers
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363908/
https://www.ncbi.nlm.nih.gov/pubmed/11437399
http://dx.doi.org/10.1054/bjoc.2001.1777
work_keys_str_mv AT kadouril cagandggcrepeatpolymorphismsintheandrogenreceptorgeneandbreastcancersusceptibilityinbrca12carriersandnoncarriers
AT eastondf cagandggcrepeatpolymorphismsintheandrogenreceptorgeneandbreastcancersusceptibilityinbrca12carriersandnoncarriers
AT edwardss cagandggcrepeatpolymorphismsintheandrogenreceptorgeneandbreastcancersusceptibilityinbrca12carriersandnoncarriers
AT huberta cagandggcrepeatpolymorphismsintheandrogenreceptorgeneandbreastcancersusceptibilityinbrca12carriersandnoncarriers
AT kotejaraiz cagandggcrepeatpolymorphismsintheandrogenreceptorgeneandbreastcancersusceptibilityinbrca12carriersandnoncarriers
AT glaserb cagandggcrepeatpolymorphismsintheandrogenreceptorgeneandbreastcancersusceptibilityinbrca12carriersandnoncarriers
AT durocherf cagandggcrepeatpolymorphismsintheandrogenreceptorgeneandbreastcancersusceptibilityinbrca12carriersandnoncarriers
AT abeliovichd cagandggcrepeatpolymorphismsintheandrogenreceptorgeneandbreastcancersusceptibilityinbrca12carriersandnoncarriers
AT peretzt cagandggcrepeatpolymorphismsintheandrogenreceptorgeneandbreastcancersusceptibilityinbrca12carriersandnoncarriers
AT eelesra cagandggcrepeatpolymorphismsintheandrogenreceptorgeneandbreastcancersusceptibilityinbrca12carriersandnoncarriers